Risk Factors for Potential Drug-Drug Interactions in Outpatients with Dyslipidemia
- PMID: 37593497
- PMCID: PMC10430412
- DOI: 10.18502/ijph.v52i7.13248
Risk Factors for Potential Drug-Drug Interactions in Outpatients with Dyslipidemia
Abstract
Background: Patients with dyslipidemia are usually multimorbid and require polypharmacy. Therefore, it is important to identify potential drug-drug interactions (pDDIs) in time to prevent their consequences. We aimed to identify and analyze risk factors contributing to their occurrence to guide health professionals.
Methods: A prospective cross-sectional study of 216 outpatients with dyslipidemia was conducted from May 2021 to April 2022 in Podgorica, the capital of Montenegro. pDDIs were identified using Medscape, Epocrates, and Drugs online interaction checkers. Multivariate regression analysis was performed to evaluate the potential predictors of interactions.
Results: pDDIs were detected in 212 (98.1%) participants, whereas pDDIs with high clinical significance were detected in 25.46%, 40.74%, and 58.8% of subjects by Drugs, Epocrates, and Medscape, respectively. Polypharmacy emerged as a risk factor for the occurrence of pDDIs in all three checkers in each category of clinical significance. The use of non-steroidal anti-inflammatory drugs and antiplatelet drugs contributes to the incidence of severe pDDIs B=1.014, 95%CI 0.681-1.346, P=0.000 and B=0.492, 95%CI 0.286-0.698, P=0.000, by Epocrates and Medscape respectively. The number of prescribers per patient was a protective factor against moderate pDDI B= -0.858, 95%CI -1.572-(-0.144), P=0.019 and B= -0.956, 95%CI -1.671-(-0.241), P=0.009, by Medscape and Epocrates, respectively, but a risk factor for the occurrence of minor pDDIs B=0.373, 95%CI 0.033-0.712 P=0.032 and B=0.143, 95%CI 0.042-0.244, P=0.006, by the same checkers.
Conclusion: Knowledge of the risk factors contributing to the occurrence of pDDIs is important for the development and implementation of strategies for their prevention, and given the high prevalence of dyslipidemia, understanding these factors seems crucial nowadays.
Keywords: Drug-drug interactions; Dyslipidemia; Interaction checker; Risk factors.
Copyright © 2023 Lalatovic et al. Published by Tehran University of Medical Sciences.
Conflict of interest statement
Conflict of Interest The authors declare that there is no conflict of interests.
Similar articles
-
Risk factors for potential drug-drug interactions in patients with chronic obstructive pulmonary disease.Ir J Med Sci. 2020 Aug;189(3):1123-1125. doi: 10.1007/s11845-019-02155-9. Epub 2019 Dec 5. Ir J Med Sci. 2020. PMID: 31807978
-
Potential drug-drug interactions in outpatients with depression of a psychiatry department.Saudi Pharm J. 2023 Feb;31(2):207-213. doi: 10.1016/j.jsps.2022.12.004. Epub 2022 Dec 15. Saudi Pharm J. 2023. PMID: 36942274 Free PMC article.
-
Clinical Pertinence and Determinants of Potential Drug-Drug Interactions in Chronic Kidney Disease Patients: A Cross-sectional Study.J Pharm Technol. 2024 Jun;40(3):142-151. doi: 10.1177/87551225241241977. Epub 2024 Apr 3. J Pharm Technol. 2024. PMID: 38784027 Free PMC article.
-
Evaluation of Drug-Related Problems in Chronic Kidney Disease Patients.Cureus. 2022 Apr 10;14(4):e24019. doi: 10.7759/cureus.24019. eCollection 2022 Apr. Cureus. 2022. PMID: 35573572 Free PMC article.
-
Evaluation of Potential Drug-Drug Interactions in Adults in the Intensive Care Unit: A Systematic Review and Meta-Analysis.Drug Saf. 2019 Sep;42(9):1035-1044. doi: 10.1007/s40264-019-00829-y. Drug Saf. 2019. PMID: 31098917
References
-
- Kopin L, Lowenstein CJ. (2017). Dyslipidemia. Ann Intern Med, 167(11):ITC81–ITC96. - PubMed
-
- Mach F, Baigent C, Catapano AL, et al. (2020). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J, 41(1):111–88. - PubMed
-
- Johnell K, Klarin I. (2007). The Relationship between Number of Drugs and Potential Drug-Drug Interactions in the Elderly A Study of Over 600 000 Elderly Patients from the Swedish Prescribed Drug Register. Drug Saf, 30(10):911–8. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous